Information  X 
Enter a valid email address

Onzima Ventures Plc (ONZ)

  Print   

Friday 11 November, 2016

Onzima Ventures Plc

Investment Update and Change of Registered Office

Onzima Ventures plc

("Onzima" or the "Company")

Investee company N4 Pharma announces latest research results for Nuvec®

Change of registered office

N4 Pharma Limited (“N4 Pharma”), in which Onzima holds a 49% equity stake, has announced that it has successfully demonstrated in-vitro transfection efficiency for its Nuvec® DNA vaccine system comparable to industry standard transfection reagents.

Its latest results show that optimised Nuvec® particles achieved 80-90% transfection efficiency in HEK 293 cells, the same levels as Lipofectamine 2000.

These results can be found here: http://www.n4pharma.co.uk/download/i/mark_dl/u/4013008883/4630405716/nuvec%20dna%20transfection%20results%201.pdf

N4 Pharma CEO Nigel Theobald commented:

“Our research on our Nuvec® particles continues to show impressive results. Lipofectamine is widely used for DNA transfection experiments as it achieves high levels of in-vitro transfection efficiency however it has been demonstrated to have negative toxic effects on cells so is not used in commercial product development for in-vivo administration.

We are continuing to build our evidence on Nuvec towards establishing its acceptability as an in-vivo delivery vector for DNA and RNA based vaccines. Our next steps are to compare the  toxicity of Nuvec® with lipofectamine® where we expect to show markedly lower toxicity of our particles making them more suitable for in-vivo use.

We are clearly able to demonstrate high transfection levels, which opens up the potential for longer term use of Nuvec® as an in-vivo transfection agent for DNA vaccines. Our R&D program is designed step by step to build the supporting case for this application for the  nuvec® system.

This latest data represents strong steady progress on the path towards commercialisation of Nuvec®. We expect further results comparing  the toxicity and transfection efficiency of Nuvec® against  a wider range of existing transfection agents in a range of  different cell types, over the next 3 or 4 months including comparison against those vectors already established for in-vivo use. ”

The Company also announces that its registered office has now changed to 6th Floor, 60 Gracechurch Street, London EC3V 0HR.

For further information please contact:  

Onzima Ventures PLC                Tel:  +44 (0) 1732 366 561
Gavin Burnell, Luke Cairns

Nominated Adviser
Cairn Financial Advisers LLP              Tel:  +44 (0) 20 7 213 0880     
Sandy Jamieson, Liam Murray

Broker
Peterhouse Corporate Finance Limited        Tel:  +44 (0) 20 7469 0930   
Guy Miller, Lucy Williams


a d v e r t i s e m e n t